Investors in Sartorius Stedim Biotech S.A. (EPA:DIM) had a good week, as its shares rose 2.4% to close at €217 following the release of its quarterly results. Sartorius Stedim Biotech reported in line with analyst predictions, delivering revenues of €762m and statutory earnings per share of €0.98, suggesting the business is executing well and in line with its plan. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.
After the latest results, the 13 analysts covering Sartorius Stedim Biotech are now predicting revenues of €3.49b in 2027. If met, this would reflect a decent 14% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to leap 54% to €5.13. Yet prior to the latest earnings, the analysts had been anticipated revenues of €3.48b and earnings per share (EPS) of €5.06 in 2027. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.
Check out our latest analysis for Sartorius Stedim Biotech
There were no changes to revenue or earnings estimates or the price target of €247, suggesting that the company has met expectations in its recent result. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. Currently, the most bullish analyst values Sartorius Stedim Biotech at €281 per share, while the most bearish prices it at €210. This is a very narrow spread of estimates, implying either that Sartorius Stedim Biotech is an easy company to value, or - more likely - the analysts are relying heavily on some key assumptions.
Of course, another way to look at these forecasts is to place them into context against the industry itself. One thing stands out from these estimates, which is that Sartorius Stedim Biotech is forecast to grow faster in the future than it has in the past, with revenues expected to display 11% annualised growth until the end of 2027. If achieved, this would be a much better result than the 1.2% annual decline over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenue grow 10% per year. So while Sartorius Stedim Biotech's revenues are expected to improve, it seems that it is expected to grow at about the same rate as the overall industry.
The Bottom Line
The most important thing to take away is that there's been no major change in sentiment, with the analysts reconfirming that the business is performing in line with their previous earnings per share estimates. Happily, there were no real changes to revenue forecasts, with the business still expected to grow in line with the overall industry. The consensus price target held steady at €247, with the latest estimates not enough to have an impact on their price targets.
Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have forecasts for Sartorius Stedim Biotech going out to 2028, and you can see them free on our platform here.
You still need to take note of risks, for example - Sartorius Stedim Biotech has 1 warning sign we think you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.